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Introduction
When readers screen the title of an article, and parts of its
abstract, they try to determine whether or not to devote their
scarce time to reading on. Some may be screening literature to
identify the articles that are systematic reviews. Thus, the main
function of an abstract of a systematic review should be to signal its
systematic methodology. For most readers, the findings described
in the abstract will also be key, either as the sole part of an article
that will be read, or to determine whether reading the full text is
required. Abstracts of systematic reviews are very important, as
some readers cannot access the full paper, such that abstracts may
be the only option for gleaning research results. This can be
because of a pay wall, low Internet download capacity, or if the full
article is only available in a language not understood by the
reader. Readers in countries where English is not the primary
language may have access to an abstract translated to their own
language, but not to a translated full text. Conversely, a large
proportion of systematic reviews are published by health
technology agencies in non-English speaking countries [1], many
of which provide only the abstract in English.
The predominance of the abstract in biomedical literature use is
clear. Within queries to PubMed, most readers look only at titles;
only half of searches result in any clicks on content [2]. The
average number of titles clicked on to obtain the abstract or full
text, even after retrieving several searches in a row, is less than five.
Of those clicks, abstracts will be represented about 2.5 times more
often than full texts of articles [2]. Even people going straight to a
PDF or full text are likely to start, and perhaps end, with reading
the abstract. The frequency of viewing full texts is somewhat
higher among people searching the Cochrane Database of
Systematic Reviews [3], but the same pattern is clear. After the
title, the abstract is the most read part of a biomedical article.
Abstracts can be useful for screening by study type [4];
facilitating quick assessment of validity [4,5]; enabling efficient
perusal of electronic search results [4,6]; clarifying to which
patients and settings the results apply [4,5]; providing readers and
peer reviewers with explicit summaries of results [5]; facilitating
the pre-publication peer review process [7]; and increasing
precision of computerised searches [6,7].
Structured abstracts were introduced in the medical literature
about 25 years ago [4–6]. They provide readers with a series of
headings, generally about the purpose, methods, results, and
conclusions of the report, and have been adopted by many
journals and conferences. They act as a prompt to the writer to
give more complete information, and facilitate the finding of
information by the reader.
Despite the adoption of structured abstracts, studies of the quality
of abstracts of clinical trials have demonstrated that improvement is
needed [8,9], and a study of systematic review abstracts demon-
strated that the direction of the effect or association could not be
determined in one in four abstracts from the general and specialty
medical literature [10]. The PRISMA Statement [11] gives some
guidance for abstracts, closely linked to commonly used headings in
structured abstracts. After observing that the quality of abstracts of
systematic reviews is still poor [10], we decided to develop an
extension to the PRISMA Statement to provide guidance on writing
abstracts for systematic reviews. We also wanted to provide a
checklist enabling the items suggested to fit into any set of headings
mandated by a journal or conference submission.
Methods for Development of the Checklist
We established a steering committee (EMB, PPG, SH, DGA). In
collaboration with the steering group of the PRISMA Statement [11],
we used the Statement to inform our selection of potential items for
the checklist of essential items that authors should consider when
reporting the primary results of a systematic review in a journal or
conference abstract. The committee generated a list of items from
PRISMA and other sources of guidance and information on
structured abstracts and abstract composition and reporting
[7,11,12], which were found using a thorough search of the literature.
In preparation for a consensus meeting, we used a modified
Delphi consensus survey method [13] to select and reduce the
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number of possible checklist items. Each item was rated by survey
participants as ‘‘omit’’, ‘‘possible’’, ‘‘desirable’’, or ‘‘essential’’ to
include in the final checklist. From the first round of the survey,
the ranked items were divided into three lists for the second round.
The first list contained the items with the highest rankings, and
participants for the second round were instructed that these would
be contained in the checklist unless they received low rankings in
the second round. The second list contained the items with
moderate rankings, and participants were instructed that these
items were likely to be removed from the checklist unless they
received high rankings in the second round. The third list
contained the items with low rankings, and participants were
instructed that these items would be removed unless they received
very high rankings in the second round.
For the third round of the Delphi survey, a draft checklist was
presented, which included only the items ranked highest in rounds
one and two. The five next highest-ranked items were then
presented, giving participants an opportunity to choose to include
these in the checklist as well.
One hundred and forty-seven participants, who were authors of
research on abstracts, established authors of systematic reviews,
methodologists or statisticians related to systematic reviews, and
journal editors, were invited by email to complete the three rounds
of the web-based survey. The response rate was 68% (n=100) for
the first round. Only those who completed round one were invited
to participate in rounds two and three. The response rate for
round two was 80% (n=80) and for round three 88% (n=88).
The results of the survey were reported at a two-day consensus-
style meeting on 13–14 October 2011, in Oxford, United
Kingdom. Fifteen invited experts attended, most of whom had
participated in the survey. The meeting began with a review of the
literature about abstract structure and content, followed by a
review of the checklist items as proposed by the survey
respondents. Meeting participants discussed the items and agreed
whether they should be included and how each item should be
worded.
Following the meeting, the checklist was distributed to the
participants to ensure it reflected the decisions made. This
explanatory document was drafted and circulated through several
iterations among members of the writing subcommittee who had
all participated in the meeting. We developed this document using
the template for the PRISMA Statement [11], which in turn was
based on the methods of the CONSORT Group [14,15].
Scope of PRISMA for Abstracts
The PRISMA for Abstracts checklist focuses on truthful
representation of a systematic review in an abstract. We developed
the checklist to help authors report all types of systematic reviews,
but recognise that the emphasis is on systematic reviews of
evaluations of interventions where one or more meta-analyses are
conducted. Authors who address questions on aetiology, diagnostic
test accuracy, or prognosis may need to modify items or include
other items in their abstract to reflect the essentials of the full
report.
The PRISMA for Abstracts Checklist
The checklist is shown in Table 1. An explanation for each item
is given below. Citations for the examples of good reporting are in
Table 2.
Section 1: TITLE
Item 1: Title.
Identify the report as a systematic review, meta-
analysis, or both.
Examples: 1a. ‘‘Systematic review and meta-analysis of the
diagnostic and therapeutic role of water-soluble contrast agent in
adhesive small bowel obstruction.’’
1b. ‘‘Inhaled corticosteroids vs placebo for preventing COPD
[chronic obstructive pulmonary disease] exacerbations: a system-
atic review and metaregression of randomized controlled trials.’’
Explanation: The abstract should make it clear that the report is
a systematic review, meta-analysis, or both (examples 1a and 1b).
Search filters have been developed to identify systematic reviews
[16], but inclusion of the words ‘‘systematic review’’ or ‘‘meta-
analysis’’ in the title may improve indexing and electronic
searching.
We also suggest using informative titles that incorporate the
PICOS approach (participants, interventions, comparators, out-
comes, and study designs). This provides key information about
the scope of the systematic review. As including all elements of the
PICOS approach may make the title unwieldy, we suggest
including the most important of these elements in the title. These
might be the elements that make this review unusual, or that assist
readers in searching for the review.
Section 2: BACKGROUND
Item 2: Objectives.
The research question including components such as
participants, interventions, comparators, and out-
comes.
Examples: 2a. ‘‘To assess the effect on survival of supportive
care and chemotherapy versus supportive care alone in advanced
NSCLC [non-small cell lung cancer].’’
2b. ‘‘To evaluate the risk of serious asthma-related events
among patients treated with formoterol.’’
2c. ‘‘The objective of this study was to investigate the predictive
value of C-reactive protein in critically ill patients.’’
Explanation: Irrespective of the strength and nature of the
results reported in the abstract, readers should be able to assess the
questions that the review intended to address. The objectives in an
abstract should convey succinctly the broad aims of the systematic
review. Objectives should reflect what the review intended to
evaluate, such as benefit (example 2a), harms (example 2b),
association, predictive value (example 2c), of the intervention or
exposure of interest and the population or context in which this is
being studied.
Summary Points
N The abstract of a systematic review should provide a
structured summary that enables a quick assessment of
the review’s validity and applicability, and easy identifi-
cation in electronic searching.
N Despite published guidance on writing the abstract in
the PRISMA Statement guiding the reporting of system-
atic reviews in general and elsewhere, evaluations show
that reporting of systematic reviews in journal and
conference abstracts is poor.
N We developed consensus-based reporting guidelines as
an extension to the PRISMA Statement on good
reporting of systematic reviews and meta-analyses in
abstracts.
N The PRISMA for Abstracts checklist gives authors a
framework for condensing their systematic review into
the essentials for an abstract that will meet the needs of
many readers.
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Section 3: METHODS
Item 3: Eligibility criteria.
Study and report characteristics used as criteria for
inclusion.
Examples – study characteristics: 3a. ‘‘We included randomised
controlled trials testing the combination of long-acting ß2- agonists
in combination with inhaled corticosteroids (ICS) versus the same
or an increased dose of ICS for a minimum of at least 28 days in
children and adolescents with asthma.’’
3b. ‘‘… randomized trials of compression stockings versus no
stockings in passengers on flights lasting at least four hours. Trials
in which passengers wore a stocking on one leg but not the other,
or those comparing stockings and another intervention were also
eligible.’’
Examples – report characteristics: 3c. ‘‘… studies published in
English, French, Spanish, Italian and German between 1966 and
July, 2008 [were included].’’
3d. ‘‘We performed a literature search of trials using
MEDLINE (January 1966–December 2001) … we retrieved
English- and non-English-language articles for review… we
searched for both published and unpublished trials…’’
Explanation: One of the key features distinguishing a systematic
review from a narrative review is the pre-specification of eligibility
criteria for including and excluding studies. A clear description of
these allows the readers to assess the applicability of the systematic
review findings [11]. Study eligibility characteristics are likely to
include the study questions (PICOS)—types of participants
included in the studies (often based on a common clinical
diagnosis), the intervention of prime interest and possibly the
specific comparison intervention, the main outcome(s) being
assessed—and acceptable study designs (examples 3a and 3b).
Eligibility criteria for reports may also include the language of
publication, the publication status (e.g., whether to include
unpublished materials and abstracts) and the year of publication
(example 3d). This is important as inclusion, or not, of studies
published in languages other than English (examples 3c and 3d),
unpublished data, or older data can influence the estimates of
effect or association in meta-analyses [17,18].
Item 4: Information sources.
Key databases searched and date of last search.
Examples: 4a. ‘‘PubMed, ERIC and Cochrane Reviews
databases from January 1980 to November 2007 were searched
for studies…’’
4b. ‘‘We searched MEDLINE, EMBASE, the Cochrane
Central Register of Controlled Trials (CENTRAL), other trial
registries and product information sheets through June 2008.’’
Explanation: The abstract should briefly indicate how thorough
and up-to-date the search was by listing key databases searched,
and the date range (example 4a) or date of last search (example
4b). We recommend that if there are three or fewer databases, list
them all; otherwise list the three that provided the majority of
included studies.
Item 5: Risk of bias assessment.
Methods for assessing risk of bias.
Example: 5a. ‘‘Risk of bias was assessed regarding randomisa-
tion, allocation sequence concealment, blinding, incomplete
outcome data, selective outcome reporting, and other biases.’’
Explanation: Problems in the design and conduct of individual
studies can raise questions about the validity of their findings [19].
For example, reports of randomised trials with inadequate
allocation sequence concealment are more likely to show
exaggerated treatment effects [20]. And non-blinded assessors of
subjective outcomes generate substantially biased effect estimates
[21,22]. It is therefore an important part of a systematic review to
assess the validity of individual studies, and the risk that they will
overestimate the true intervention effect. Authors should describe
any methods they used to assess the risk of bias in the included
studies (example 5a).
Table 1. The PRISMA for Abstracts Checklist.
TITLE
1. Title: Identify the report as a systematic review, meta-analysis, or both.
BACKGROUND
2. Objectives: The research question including components such as participants, interventions, comparators, and outcomes.
METHODS
3. Eligibility criteria: Study and report characteristics used as criteria for inclusion.
4. Information sources: Key databases searched and search dates.
5. Risk of bias: Methods of assessing risk of bias.
RESULTS
6. Included studies: Number and type of included studies and participants and relevant characteristics of studies.
7. Synthesis of results: Results for main outcomes (benefits and harms), preferably indicating the number of studies and participants for
each. If meta-analysis was done, include summary measures and confidence intervals.
8. Description of the effect: Direction of the effect (i.e., which group is favoured) and size of the effect in terms meaningful to clinicians and
patients.
DISCUSSION
9. Strengths and Limitations of evidence: Brief summary of strengths and limitations of evidence (e.g., inconsistency, imprecision, indirectness, or risk of bias,
other supporting or conflicting evidence).
10. Interpretation: General interpretation of the results and important implications.
OTHER
11. Funding: Primary source of funding for the review.
12. Registration: Registration number and registry name.
doi:10.1371/journal.pmed.1001419.t001
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Table 2. List of references used as examples.
Example Number Citation
1a. Branco BC, Barmparas G, Schuriger B, Inaba K, et al. (2010) Systematic review and meta-analysis of the diagnostic and therapeutic role of
water-soluble contrast agent in adhesive small bowel obstruction. British Journal of Surgery 97: 470–478.
1b. Agarwal R, Aggarwal AN, Gupta D, Jindal SK (2010) Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic
review and metaregression of randomized controlled trials. Chest 137(2): 318–325.
2a. Non-Small Cell Lung Cancer Collaborative Group (2010) Chemotherapy and supportive care versus supportive care alone for advanced
non-small cell lung cancer. Cochrane Database of Systematic Reviews. Issue 5, Art. No. CD007309. DOI:10.1002/14651858.CD007309.pub2.
2b. Kemp J, Armstrong L, Wan Y, Alagappan VKT, Ohlssen D, Pascoe S (2011) Safety of formoterol in adults and children with asthma: a meta-
analysis. Annals of Asthma, Allergy and Immunology 107(1): 71–78.
2c. Zhang Z, Ni H (2011) C-reactive protein as a predictor of mortality in critically ill patients: a meta-analysis and systematic review.
Anaesthesia and Intensive Care 39(5): 854–861.
3a. Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM (2009) Addition of long-acting beta-agonists to inhaled corticosteroids for chronic
asthma in children. Cochrane Database of Systematic Reviews Issue 3. Art. No. CD007949. DOI:10.1002/14651858.CD007949.
3b. Clarke MJ, Hopewell S, Juszczak E, Eisinga A, Kjeldstrøm M (2006) Compression stockings for preventing deep vein thrombosis in airline
passengers. Cochrane Database of Systematic Reviews. Issue 2, Art. No. CD004002. DOI:10.1002/14651858.CD004002.pub2.
3c. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO (2003) Corticosteroids for maintenance of remission in Crohn’s disease.
Cochrane Database of Systematic Reviews Issue 4. Art. No. CD000301. DOI:10.1002/14651858.CD000301.
3d. Trinh NH, Hoblyn J, Mohanty S, Yaffe K (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and
functional impairment in Alzheimer disease: a meta-analysis. Journal of the American Medical Association 289(2): 210–216.
4a. Bonuck KA, Freeman K, Henderson J (2009) Growth and growth biomarker changes after adenotonsillectomy: systematic review and
meta-analysis. Archives of Disease in Childhood 94: 83–91. DOI:10.1136/adc.2008.141192.
4b. Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180(1):
32–39.
5a. Cho S-H, Lee H, Ernst E (2010) Acupuncture for pain relief in labour: a systematic review and meta-analysis. BJOG 117: 907–920.
6a. Huss A, Scott P, Stuck AE, Trotter C, Egger M (2009) Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 180(1): 48–58.
6b. Alexander LD, Gilman DRD, Brown DR, Brown JL, Houghton PE (2010) Exposure to low amounts of ultrasound energy does not improve
soft tissue shoulder pathology: a systematic review. Physical Therapy 90(1): 14–25.
7a. Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA (2011) Meta-analysis: cardiac resynchronization therapy for patients with less
symptomatic heart failure. Annals of Internal Medicine 154: 401–412.
7b. Wilson A, Gallos ID, Plana N, Lissauer D, Khan KS, Zamora J et al (2011) Effectiveness of strategies incorporating training and support of
traditional birth attendants on perinatal and maternal mortality: meta-analysis. BMJ 343: d7102. DOI: 10.1136/bmj.d7102
7c. Gillies M, Palmateer N, Hutchinson S, Ahmed S, Taylor A, Goldberg D (2010) The provision of non-needle/syringe drug injecting
paraphernalia in the primary prevention of HCV among IDU: a systematic review. BMC Public Health 10: 721.
8a. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR (2009) Radial versus femoral access for coronary angiography or intervention and the
impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. American Heart Journal
157(1): 132–140.
8b. Lam LL, Cameron PA, Schneider HG, Abramson MJ, Muller C, et al. (2010) Meta-analysis: effect of B-type natriuretic peptide testing on
clinical outcomes in patients with acute dyspnea in the emergency setting. Annals of Internal Medicine 153(11): 728–735.
8c. Madsen MV, Gøtzsche PC, Hrobjartsson A (2009) Acupuncture treatment for pain: systematic review of randomised clinical trials with
acupuncture, placebo acupuncture, and no acupuncture groups. BMJ 338: a3115. DOI:10.1136/bmj.a3115.
9a. Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S et al (2010) Meta-analysis: age and effectiveness of prophylactic implantable
cardioverter-defibrillators. Annals of Internal Medicine 153(9): 592–599.
9b. Ceglia L, Lau J, Pittas AG (2006) Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Annals of
Internal Medicine 145(9): 665–675.
9c. Lin J S, O’Connor E, Whitlock EP, Beil TL (2010) Behavioral counseling to promote physical activity and a healthful diet to prevent
cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 53(11): 736–
750.
9d. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, et al. (2009) Systematic review: sodium bicarbonate treatment regimens for the
prevention of contrast-induced nephropathy. Annals of Internal Medicine 151: 631–638.
10a. Chandra D, Parasini E, Mozaffarian D (2009) Meta-analysis: travel and risk for venous thromboembolism. Annals of Internal Medicine
151(3): 180–190.
10b. Thomson H, Thomas S, Sellstrom E, Petticrew M (2009) The health impacts of housing improvement: a systematic review of intervention
studies from 1887 to 2007. American Journal of Public Health 99 Suppl 3: S681–S692.
10c. Wells G, Parkash R, Healey JS, Talajic M, Arnold M, Sullivan S, et al. (2011) Cardiac resynchronization therapy: a meta-analysis of
randomized controlled trials. CMAJ 183(4): 421–429. DOI:10.1503/cmaj.101685.
11a. Levy G, Hill MJ, Ramirez CI, Correa L, Ryan ME, et al. (2012) The use of follicle flushing during oocyte retrieval in assisted reproductive
technologies: a systematic review and meta-analysis. Human Reproduction 27(8): 2373–2379.
11b. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, et al. (2012) Lithium toxicity profile: a systematic review and meta-analysis.
Lancet 379(9817): 721–728. DOI:10.1016/S0140-6736(11)61516-X.
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Many tools exist for assessing the overall risk of bias in included
studies, including scales, checklists and individual components
[23]. Most tools are scales in which various components of quality
are scored and combined to give a summary score. This approach
can be seriously misleading, however, and should be discouraged.
A preferred approach requires authors to specify which individual
methodological components they will assess and to provide a
description and judgment for each component for each of the
studies assessed [19]. For randomised trials, common components
include: appropriate generation of the allocation sequence [24],
concealment of the allocation sequence [20], blinding of partic-
ipant and health care providers, blinding of outcome assessors
[22], assessment of incomplete outcome data [25], and selective
outcome reporting [26].
Section 4: RESULTS
Item 6: Included studies.
Number and type of included studies and partici-
pants, and relevant characteristics of studies.
Examples: 6a. ‘‘We included 22 trials involving 101 507
participants: 11 trials reported on presumptive pneumococcal
pneumonia, 19 on all-cause pneumonia and 12 on all-cause
mortality. The current 23-valent vaccine was used in 8 trials.’’
6b. ‘‘Eight studies included in this review (n = 586 patients,
median PEDro score = 8.0/10) evaluated various parameters,
including the duration of patients’ symptoms (0–12 months), duty
cycle (20% and 100%), intensity (0.1–2.0 W/cm2), treatment time
per session (4.5–15.8 minutes), number of treatments (6–39), and
total energy applied per treatment (181–8,152 J).’’
Explanation: The number of studies, number of participants,
and characteristics of the included studies (examples 6a and 6b)
enable readers to gauge the validity and applicability of the
systematic review’s results. These characteristics might include
descriptors of the participants (e.g., age, severity of disease), range
of interventions used (e.g., dose and frequency of drug adminis-
tration), and measurement of outcomes (e.g., follow-up times).
Item 7: Synthesis of results.
Results for main outcomes (benefits and harms),
preferably indicating the number of studies and partic-
ipants for each. If meta-analysis was done, include
summary measures and confidence intervals.
Examples: 7a. ‘‘… CRT [cardiac resynchonization therapy]
reduced all-cause mortality (6 trials, 4572 participants; risk ratio
[RR], 0.83 [95% CI, 0.72 to 0.96]) and heart failure hospitaliza-
tions (4 trials, 4349 participants; RR, 0.71 [CI, 0.57 to 0.87])
without improving functional outcomes or quality of life.’’
7b. ‘‘Six studies reported on maternal mortality and our meta-
analysis showed a non-significant reduction (three randomised
trials, relative risk 0.79, 0.53 to 1.05, P= 0.12; three non-
randomised studies, 0.80, 0.44 to 1.15, P = 0.26).’’
7c. ‘‘Eight studies presented adjusted odds ratios, ranging from
0.3 to 0.9, suggesting a reduced likelihood of self-reported sharing
of non-N/S [non-needle/syringe] injecting paraphernalia associ-
ated with use of NSP [needle and syringe exchange programmes]
or SIF [safer injection facilities].’’
Explanation: The results for the main outcomes should be given
in the abstract. If meta-analyses have been done, include for each
the summary measure (estimated effect) and confidence interval. If
the intention had been to perform meta-analysis, but no meta-
analysis was done for one or more main outcomes, the reasons
should be stated (e.g., heterogeneity too great).
The abstract should make clear the protocol-defined, pre-
specified importance of each outcome reported, and should not
report only those outcomes that have statistically significant or
clinically important results.
Where possible, given space limitations, the number of studies
and participants for each main outcome should be stated,
particularly if only a small proportion of the total number of
studies or patients in the systematic review contributed informa-
tion on a particular outcome.
If there are no summary measures, some numerical data may
still be given (example 7c), although authors should be wary of
making this in the form of ‘‘vote counting’’ where the number of
‘‘positive’’ and ‘‘negative’’ studies is given. Vote counting takes no
account of weighting of studies according to the amount of
information they contain [27].
Item 8: Description of effect.
Direction of the effect (i.e., which group is favoured)
and size of the effect in terms meaningful to patients and
clinicians.
Examples: 8a. ‘‘Radial access reduced major bleeding by 73%
compared to femoral access (0.05% vs 2.3%, OR 0.27 [95% CI
0.16, 0.45], P,0.001).’’
8b. ‘‘Length of hospital and critical care unit stay were both
modestly reduced in the tested group compared with the control
group, with a mean difference of 21.22 day (CI, 22.31 to 20.14
day) and 20.56 day (CI, 21.06 to 20.05 day), respectively.’’
8c. ‘‘A small difference was found between acupuncture and
placebo acupuncture: standardised mean difference 20.17 (95%
confidence interval 20.26 to 20.08)… [in favour of acupunc-
ture]…, corresponding to 4 mm (2 mm to 6 mm) on a 100 mm
visual analogue scale.’’
Explanation: The results should summarise the main outcomes
in words and numbers. The wording should indicate the direction
of the effect (e.g., lower, fewer, reduced; greater, more, increased)
and the size of the effect using familiar units such as percentages,
days, or kilograms. Example 8a makes clear the size of the effect
even for readers who have difficulty interpreting relative risks and
confidence intervals. When a percentage is used, the baseline risk
should also be shown, which allows the reader to see what the
absolute benefit or harm is, and calculate whichever measures they
choose (example 8a). Authors should take care to make it clear
whether the reported measure is an absolute or a relative one (e.g.,
where percentage is used as the units of measurement). Where
possible, continuous outcome measures should be expressed in
Table 2. Cont.
Example Number Citation
12a. Timmons BW, Leblanc AG, Carson V, Connor Gorber S, Dillman C, et al. (2012) Systematic review of physical activity and health in the early
years (aged 0–4 years). Applied Physiology, Nutrition and Metabolism 37(4): 773–792.
12b. Stradling C, Chen YF, Russell T, Connock M, Thomas GN, et al. (2012) The effects of dietary intervention on HIV dyslipidaemia: a systematic
review and meta-analysis. PLoS ONE 7(6):e38121. Epub 2012 Jun 11.
doi:10.1371/journal.pmed.1001419.t002
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familiar units (example 8b), particularly when the standardised
mean difference is used (example 8c).
Section 5: DISCUSSION
Item 9: Strengths and limitations of evidence.
Brief summary of strength and limitations of evidence
(e.g., inconsistency, imprecision, indirectness, or risk of
bias, other supporting or conflicting evidence).
Examples: 9a. ‘‘Four potentially eligible trials were not included
in the meta-analysis because mortality data by age group were not
available.’’
9b. ‘‘All trials were open label, which may introduce bias. Most
of the trials were of 24 weeks’ duration or less, limiting assessment
of long-term safety.’’
9c. ‘‘Meta-analyses for some outcomes had large statistical
heterogeneity or evidence for publication bias. Only 11 trials
followed outcomes beyond 12 months.’’
9d. ‘‘Meta-regression showed that small, poor-quality studies
that assessed outcomes soon after radiocontrast administration
were more likely to suggest benefit (P,0.05 for all).’’
Explanation: The abstract should briefly describe the strengths
and limitations of the evidence across studies [28]. Limitations
may include: risk of bias common to many or all studies, such as
lack of blinding for subjective outcomes (example 9b) or
unavailability of data (example 9a); inconsistency of effect or
association, as demonstrated by high heterogeneity (examples 9c
and 9d); imprecision, e.g., due to few events or small sample sizes;
indirectness of the evidence, such as the use of an intermediate or
short-term outcome (examples 9b and 9c); and likely publication
bias (example 9c). Potential strengths of the overall body of
evidence that might apply for a particular outcome of a systematic
review include: a large effect (example 8a); demonstration of a
dose-response relationship (example 10a, below); and that all
biases would be likely to reduce the effect rather than increase it.
One or more of these strengths and limitations may apply to each
of the outcomes of the systematic review being described in the
abstract. Some of this information may be combined with item 6,
above, when describing the included studies, however a summary
of the overall strengths and limitations of the evidence might also
be helpful.
Item 10: Interpretation.
General interpretation of the results and important
implications.
Examples: 10a. ‘‘Travel is associated with a nearly 3-fold higher
risk for VTE [venous thromoboembolism], with a dose-response
relationship of 18% higher risk for each 2-hour increase in travel
duration.’’
10b. ‘‘Housing improvements, especially warmth improve-
ments, can generate health improvements; there is little evidence
of detrimental health impacts. The potential for health benefits
may depend on baseline housing conditions and careful targeting
of the intervention. Investigation of socioeconomic impacts
associated with housing improvement is needed to investigate
the potential for longer-term health impacts.’’
10c. ‘‘The cumulative evidence is now conclusive that the
addition of cardiac resynchronization to optimal medical therapy
or defibrillator therapy significantly reduces mortality among
patients with heart failure.’’
Explanation: Remembering that some readers may struggle
with interpreting the statistical results, an overall summary of the
main effects—positive or negative—should be given (example
10a). This could include an indication of what is clear (example
10c), what important uncertainties remain (example 10b), and
whether there is ongoing research addressing these.
If there is insufficient evidence from well-conducted studies to
answer the review’s question, this should be made clear to the
reader. When the results are not statistically significant, authors
should distinguish between those where there is insufficient
evidence to rule out a difference between treatments (wide
confidence interval), and those which have sufficient evidence
that an important difference is unlikely (narrow confidence
interval).
If the conclusions of the review differ substantially from previous
systematic reviews, then some explanation might also be provided.
Reference could be made to known ongoing studies that have the
potential to change the result of the review. Possible implications
for policy and practice should be stated.
Section 6: OTHER
Item 11: Funding.
Primary source of funding for the review.
Examples: 11a. ‘‘This work was supported, in part, by the
Program in Reproductive and Adult Endocrinology, NICHD,
NIH, Bethesda, MD. The authors have no competing interests to
declare.’’
11b. ‘‘Funding: National Institute for Health Research
Programme Grant for Applied Research.’’
Explanation: Studies of the relationship between pharmaceuti-
cal company funding and results of clinical trials have shown that
sponsored studies are more likely to have outcomes favouring the
sponsor [29,30]. This is also the case for systematic reviews [31].
Therefore, the abstract should indicate whether the sponsor of the
research or the researchers might have a conflict of interest in
respect of the findings of the systematic review, for example, as the
manufacturer of the intervention being evaluated (examples 11a
and 11b). The abstract should include the main source of funding
for the systematic review, whether from host institutions or from
external bodies.
Item 12: Registration.
Registration number and registry name.
Examples: 12a. ‘‘PROSPERO registration: CRD42011
001243.’’
12b. ‘‘PROSPERO 2011:CRD42011001329.’’
Explanation: Registration of systematic reviews provides a
record of reviews that have been initiated, even if they have not
been published. It is therefore a means of alerting researchers to
systematic reviews that are in progress, and serves as a public
record of the proposed systematic review. It also helps to detect
reporting bias by enabling better identification of unpublished
systematic reviews, and also to compare the methods or outcomes
reported in published reviews with those originally proposed in
registered protocols [32]. The abstract should record the name of
the database with which the review is registered, and the
registration number. Cochrane reviews are an exception to this
requirement, as they are preceded by a peer reviewed protocol
that is published in the Cochrane Library and can be downloaded
from there.
Discussion
The title of a systematic review is its first signal of its relevance to
potential readers. Few titles will entice a reader to invest additional
time, but when they do, they ordinarily start—and quite often
end—with the abstract. The first impression is therefore crucial.
We strongly recommend the use of structured abstracts for
reporting systematic reviews, as does the PRISMA Statement [11].
We recognise that journals have developed their own set of
headings that are considered appropriate for reporting systematic
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reviews, and it is not our intention to suggest changes to these
headings, but to recommend what should be reported under them.
The order of items and the headings are therefore flexible. For
example, the strengths and limitations may be stated at the end of
the Results, under a separate heading, or with the Discussion or
Conclusions, depending on journal requirements. It may also be
possible to combine items from the checklist into one sentence. For
example, limitations may be combined with a description of the
included studies (i.e., items 6 and 9 from the checklist).
We have suggested reporting a minimum set of items. We do
not advocate that abstracts replace full articles in informing
decision making, but we recognise that for many time-pressed
readers, or for those with limited access to the full texts of reports,
it is important that abstracts contain as much information as is
feasible within the word limit of abstracts. Indeed, for readers who
do not understand the language of publication of the article, the
translated abstract may have far more relevance than the full-text
article.
A checklist is not sufficient to ensure good abstract writing. For
example, the abstract should clearly and truthfully reflect the full
report, and not selectively report results that are statistically
significant while not referring to those that were not. Similarly, the
abstract should only draw conclusions that are substantiated by
data from the full report and analyzed as described in the protocol,
rather than selectively emphasising interesting results that were a
minor or ad hoc component of the analysis. In brief, the abstract
should be an unbiased representation of the full report. We also
suggest that peer and editorial review processes related to the
abstract should explicitly check this.
A particularly difficult area is the Discussion section of an
abstract. The checklist includes two items with several elements.
We suggest that authors let the reader know whether they feel their
question has been answered, or whether there is still uncertainty
before presenting practice and policy implications. These state-
ments should be clearly backed by the results given in the abstract,
and by presentation of the strengths and limitations of the evidence
in the review.
We encourage journals and conference organisers to endorse
the use of PRISMA for Abstracts, in a similar way to CONSORT
for Abstracts [33]. This may be done by modifying their
instructions to authors and including a link to the checklist on
their website. It has been demonstrated that the number of
checklist items reported is improved in journals that require
checklist completion as part of the submission process [34].
Abstracts should not replace full articles in informing decision
making, but for time-pressed readers and those with limited access
to full text reports, the abstract must stand alone in presenting a
clear and truthful account of the research. The PRISMA for
Abstracts checklist will guide authors in presenting an abstract that
facilitates a quick assessment of review validity, an explicit
summary of results, facilitates pre-publication or conference
selection peer review, and enables efficient perusal of electronic
search results.
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